Supplemental Figure 7 shows relapsed or primary refractory AML patients demonstrate reduced ex vivo drug sensitivity compared to diagnosis AML patients.
No takes yet. Share an insight, caveat, or question.
Olesinski et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: